News

AddToAny

Google+ Facebook Twitter Twitter

Chlamydia vaccine on horizon

The first ever chlamydia vaccine to reach phase 1 clinical trial has been found to be safe and able to provoke an immune response.

The randomised controlled trial of 35 healthy women demonstrates promising early signs of what could be an effective vaccine.

However, further trials are required to determine whether the immune response it provokes effectively protects against chlamydia infection.

Chlamydia, caused by the bacterium Chlamydia trachomatis, presents a major global health burden, with 131 million new cases occurring annually. 

But as three out of four infections are symptomless, this number is likely to be underestimated. The most new cases are found in teenagers and young adults.

Vaccination may be the best way to tackle the epidemic, as national treatment programmes have largely failed to curb the epidemic, despite availability of diagnostic tests and effective antibiotic treatment. 

Image credit | iStock

Related Articles

The microbe that stops malaria

Scientists have discovered a microbe that completely protects mosquitoes from being infected with malaria.

COVID 19: a report from the Isle of Man

Chief Biomedical Scientist in Biochemistry Charlie Houston and colleagues outline the impact of COVID-19 on the Isle of Man.

Lab-quality microscope for £15

For the first time, labs around the world can 3D print their own precision microscopes to analyse samples and detect diseases, thanks to an open-source design created at the University of Bath.

Top